Corpus Intelligence IC Memo — NEW YORK EYE AND EAR INFIRMARY 2026-04-26 10:37 UTC
IC Memo — NEW YORK EYE AND EAR INFIRMARY
Investment Committee Memorandum | NY | 15 beds | Grade D | EBITDA uplift $8.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NEW YORK EYE AND EAR INFIRMARY

CCN 330100 | NEW YORK, NY | 15 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

NEW YORK EYE AND EAR INFIRMARY is a 15-bed under-performing / distressed in NEW YORK, NY with $112.8M in net patient revenue and a -28.0% operating margin. The hospital serves a payer mix of 1.1% Medicare, 0.1% Medicaid, and 98.8% commercial.

Thesis: Turnaround. Our ML models identify $8.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -28.0% to -20.6% (+736bps).

Net Revenue HCRIS$112.8M
Current EBITDA COMPUTED$-31.5M
Operating Margin COMPUTED-28.0%
Occupancy HCRIS15.4%
Revenue / Bed COMPUTED$7.5M
Net-to-Gross HCRIS27.0%
Distress Probability ML44.1%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
25
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -28.0% places it below the state median. Among 25 size-comparable peers (8-30 beds), the median margin is -14.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (8-30), prioritizing same-state peers. 25 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NEW YORK EYE AND EAR INFIRMARY (Target)NY15$112.8M-28.0%
LEWIS COUNTY GENERAL HOSPITALNY25$70.3M-17.6%
CARTHAGE AREA HOSPITALNY25$59.4M-12.3%
SUNNYVIEW HOSPITAL AND REHABILNY17$56.6M-9.4%
COMMUNITY MEMORIAL HOSPITALNY25$53.2M-6.7%
MASSENA MEMORIAL HOSPITALNY25$48.4M-14.4%
ELIZABETHTOWN COMMUNITY HOSPITNY25$47.4M-7.8%
ST. JAMES HOSPITALNY15$46.3M-27.4%
LITTLE FALLS HOSPITALNY25$42.5M7.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.4M+210bp18mo
Cost to Collect4.5%2.5%$2.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.4M+122bp9mo
Clean Claim Rate88.0%96.0%$72K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.4M
Cost to Collect
$2.3M
Denial Rate Reduction
$2.2M
A/R Days Reduction
$1.4M
Clean Claim Rate
$72K
Total EBITDA Uplift$8.3M
Current EBITDA$-31.5M
+ RCM Uplift+$8.3M
Pro Forma EBITDA$-23.2M
Current Margin-28.0%
Pro Forma Margin-20.6%
WC Released (1x)$4.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-48.5M$-125.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-48.5M$-153.2M0.00x-100.0%
Bull Case9.0x11.0x$-43.7M$-141.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-43.7M$-167.4M0.00x-100.0%
Bear Case11.0x10.0x$-53.4M$-150.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-53.4M$-183.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 15.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 25 hospitals with 8-30 beds
  • Same-state prioritization (n=26)
  • Comp margins: P25=-25.7% / P50=-14.5% / P75=-7.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.